Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
The DalPhos ligands were developed by Prof. Mark Stradiotto and his research team at the Department of Chemistry, Dalhousie University
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
The joint partnership, powered by Cloudbyz Clinical Research Management Platform and ClinChoice's industry-leading transformation services, will provide an end-to-end clinical research management technology platform and services to customers
The peptide-based vaccine induces a t cell-dependent response
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
Collaboration awarded €3 million grant by the Bill & Melinda Gates Foundation
The expansion positions Cambrex with the largest and most advanced API facility in the United States
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
These distinct gut microbial signatures can be used to predict the risk of developing long Covid and diagnose long Covid in patients with persistent symptoms after the acute infection
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
The site consists of five fermentation "mini-factories" capable of concurrently producing our more than 13 currently scaled and future bio-fermented products
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
An intuitive monitor featuring a patient-tailored approach is now in clinical use in select centres in U.S. and Europe
Subscribe To Our Newsletter & Stay Updated
